Loading patent…
AssigneeMedImmune Vaccines, Inc.
InventorsRichard Schwartz, John Berry, Ajit Subramanian, Xiao Shi
Estimating the term…
The present invention provides novel MDCK-derived adherent non-tumorigenic cell lines that can be grown in the presence or absence of serum. The cell lines of the present invention are useful for the production of vaccine material (e.g., viruses). More specifically, the cell lines of the present invention are useful for the production of influenza viruses in general and ca/ts influenza viruses in particular. The invention further provides methods and media formulations for the adaptation and cultivation of MDCK cells such that they remain non-tumorigenic. Additionally, the present invention provides methods for the production of vaccine material (e.g., influenza virus) in the novel cell lines of the invention.
A cell culture composition comprising non-tumorigenic MDCK cells which are derivatives of the cell line MDCK (ATCC CCL34).
A non-tumorigenic MDCK cell line selected from the group consisting of:
A process for preparing an adherent, non-tumorigenic MDCK cell line that can be cultivated in serum-containing media and which can be infected by influenza viruses, which comprises the steps;
A process for preparing an adherent, non-tumorigenic MDCK cell line that can be cultivated in serum-free media and which can be infected by influenza viruses, which comprises the steps;
A media formulation selected from the group consisting of:
Dependencies are inferred from the claim text.